Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2023 Earnings Call Transcript

Sukumar Nagendran: And also I think your question was with reference to autonomic abnormalities, right, seen in these patients. So, I’ll break this down for you. So remember, in these adult patients who’ve been referred into this single center in Montreal, they do have physicians who’ve been taking care of them now for a very long time, so you have the medical history that allow as documents, the abnormalities seen, whether it’s in sleep, seizure history, respiratory abnormalities or GI function. Also, when it comes to sleep, usually these patients also have sleep lab evaluations whenever appropriate and possible that documents the abnormalities that are observed. When it comes to seizures that are usually seizure diaries, parental diaries, and also EEG activities that have been measured that give you some sense of how often these seizures happen.

And then when it comes to GI dysfunction, it depends on clinical reports, but also sometimes you do mobility studies in these patients, that may give you a good sense how abnormal GI function could be. So those are the general parameters that are used to make these assessments. And then the PI obviously does the assessments based on past history and then post-treatment evaluation for the protocol. And then finally, some of these questionnaires scales that Sean was referring to may have subtle questions or obvious questions that give you some hint of is, are there continued sleep abnormalities, are there continued demo motor dysfunction, are there continued respiratory abnormalities, et cetera. So it’s a collective assessment of each patient over time.

Silvan Tuerkcan: And just regarding the dosing of the — not the third patient, but then at the higher, going to the higher dose, is there another DSMB meeting required to switch the higher dose post dosing of the third patient? Thank you so much.

Sukumar Nagendran: Yes. Once the third patient is dosed, you wait six weeks and then you collect the data, clean the database, and then you have to meet with the IDMC or DSMB before you go to the higher dose cohort of 1E15.

Operator: The next question comes from Eun Yang from Jefferies. Please proceed with your question. And it seems like we no longer have Eun connected on the line, and at this time there are no further questions in the queue. Ladies and gentlemen, we have reached the end of the question-and-answer session, and I’d like to turn the call back to Sean Nolan for closing remarks. Thank you, Sean.

Sean Nolan: Just want to thank everyone for attending the call. We appreciate the questions and look forward to speaking again soon. Take care.

Operator: Thank you. Ladies and gentlemen, that does conclude today’s conference. Thank you very much for joining us. You may now disconnect your lines.